The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase
Open accessAbstract
The cytosine analog 5-aza-2′-deoxycytidine has been used clinically to reactivate genes silenced by DNA methylation. In particular, patients with β-thalassemia show fetal globin expression after administration of this hypomethylating drug. In addition, silencing of tumor suppressor gene expression by aberrant DNA methylation in tumor cells may potentially be reversed by a similar regimen. Consistent with its function in maintaining tumor suppressor gene expression, 5-aza-2′-deoxycytidine significantly reduces intestinal tumor multiplicity in the predisposed Min mouse strain. Despite its utility as an anti-cancer agent, the drug is highly mutagenic by an unknown mechanism. To gain insight into how 5-aza-2′-deoxycytidine induces mutations in vivo , we examined the mutational spectrum in an Escherichia coli lac I transgene in colonic DNA from 5-aza-2′-deoxycytidine-treated mice. Mutations induced by 5-aza-2′-deoxycytidine were predominantly at CpG dinucleotides, which implicates DNA methyltransferase in the mutagenic mechanism. C:G→G:C transversions were the predominant class of mutations observed. We suggest a model for how the mammalian DNA methyltransferase may be involved in facilitating these mutations. The observation that 5-aza-2′-deoxycytidine-induced mutations are mediated by the enzyme suggests that novel inhibitors of DNA methyltransferase, which can inactivate the enzyme before its interaction with DNA, are needed for chemoprevention or long term therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells
Lei, H., Oh, S. P., Okano, M., Jüttermann, R., Goss, K. A., Jaenisch, R., & Li, E. (1996) · Development · doi:10.1242/dev.122.10.3195 · Cited by 816
Self-citationOn the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs
Santi, D. V., Garrett, C. E., & Barr, P. J. (1983) · Cell · doi:10.1016/0092-8674(83)90327-6 · Cited by 401
Cited by
Gene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,344
Self-citationChristman, J. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205699 · Cited by 1,525
Dna Hypomethylation In Cancer Cells
Ehrlich, M. (2009) · Epigenomics · doi:10.2217/epi.09.33 · Cited by 1,060
Metadata
- Authors
- Jackson-Grusby, L., Laird, P. W., Magge, S. N., Moeller, B. J., & Jaenisch, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-04-29
- Volume
- 94
- Issue
- 9
- Pages
- 4681-4685
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1964302569
- Cited by
- 208
- References
- 5
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. https://app.cochat.ai/papers/10.1073/pnas.94.9.4681
- The paper
- Jackson-Grusby, L., Laird, P. W., Magge, S. N., Moeller, B. J., & Jaenisch, R. (1997). Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.94.9.4681
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.